Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
MOP ENV SOL	MOPN	OTC Markets	0	0.0001 USD	Stock
STERLING BUS SOL	STLB	OTC Markets	400	0.00005 USD	Stock
IMPLEMENTA SOL AB	IMSOL B	NORDIC GROWTH MARKET	112,253	0.096 SEK	Stock
SOL-GEL TECHNOLOGIES LTD.	SLGL	Nasdaq +2 Other	25,139	0.8504 USD	Stock
SOL-GEL TECHNOLOGIES LTD.	4SG	Deutsche Boerse AG	-	0.755 EUR
SOL-GEL TECHNOLOGIES LTD.	4SG	Börse Stuttgart	-	0.76 EUR
AD-SOL NISSIN CORPORATION	3837	Japan Exchange +1 Other	14,362	1,625 JPY	Stock
AD-SOL NISSIN CORPORATION		Japan Exchange	-	- JPY
AUTOPISTAS DEL SOL SA	AUSO	Buenos Aires S.E.	55,570	2,914 ARS	Stock
SOL S.P.A.	SOL	Borsa Italiana +5 Other	26,937	34.45 EUR	Stock
SOL S.P.A.	0NJP	London S.E.	25	27 EUR
SOL SPA	0NJP	CINNOBER BOAT	-	- EUR
SOL S.P.A.	QOL	Börse Stuttgart	-	33.5 EUR
SOL S.P.A.	QOL	Deutsche Boerse AG	-	34.75 EUR
SOL S.P.A.	QOL	BOERSE MUENCHEN	-	34.6 EUR
SOL GLOBAL INVESTMENTS CORP.	SOL	Canadian Securities Exchange +3 Other	65,796	0.05 CAD	Stock
SOL GLOBAL INVESTMENTS CORP.	9SB	Deutsche Boerse AG	-	0.0205 EUR
SOL GLOBAL INVESTMENTS CORP.	9SB	Börse Stuttgart	-	0.0265 EUR
SOL GLOBAL INVESTMENTS CORP.	SOLCF	OTC Markets	10,879	0.0369 USD
SHINHAN ASSET MANAGEMENT CO LTD - SHINHAN SOL 200 TOP10 ETF	A411540	Korea S.E.	2,363	8,715 KRW	Stock
SHINHAN ASSET MANAGEMENT - SOL IHS MARKIT GLOBAL CARBON EMISSION(SYNTHETIC) ETF	A400590	Korea S.E.	21,007	11,965 KRW	Stock

See all

News (161)

ContraFect Corporation Announces Management Resignations	12-05	CI
VedaBio Unveils World Class Scientific Advisory Board	11-08	AQ
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	20/06/23	AQ
Teva Pharmaceutical Industries : FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Sol Barer	20/06/23	PU
TEVA PHARMACEUTICAL INDUSTRIES LTD : Submission of Matters to a Vote of Security Holders (form 8-K)	15/06/23	AQ
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates	28/03/23	AQ
Teva Announces Appointment of Richard Francis as President and CEO	21/11/22	BU
ContraFect : Submission of Matters to a Vote of Security Holders - Form 8-K	19/05/22	PU
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	19/05/22	AQ
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors	10/05/22	GL
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors	17/02/22	GL
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors	17/02/22	GL
Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicine	22/11/21	BU
ContraFect : Corporate Presentation	25/08/21	PU
CERECOR : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	02/08/21	AQ
Cerecor : Management Change/Compensation (Form 8-K)	21/06/21	PU
CERECOR INC. : Change in Directors or Principal Officers (form 8-K)	21/06/21	AQ
Cerecor Inc. Announces Board Changes	21/06/21	CI
Cerecor : Submission of Matters to a Vote of Security Holders (Form 8-K)	16/06/21	PU
CERECOR INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	16/06/21	AQ
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	21/05/21	AQ
CERECOR : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	13/05/21	AQ
ContraFect : Corporate Presentation	31/03/21	PU
CERECOR : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	08/03/21	AQ
Cerecor : LATEST IR PRESENTATION COMPANY OVERVIEW	02/03/21	PU
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member	19/01/21	GL
CERECOR : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/11/20	AQ
Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors	29/10/20	GL
Cerecor : Appoints Gilla Kaplan, Ph.D., to the Board of Directors	13/10/20	AQ
Cerecor : Appoints Gilla Kaplan, Ph.D., to the Board of Directors	12/10/20	AQ
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors	12/10/20	GL
ContraFect : Corporate Presentation	20/07/20	PU
CERECOR INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	18/06/20	AQ
TEVA PHARMACEUTICAL INDUSTRIES LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	09/06/20	AQ
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	13/05/20	AQ
CERECOR : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	07/05/20	AQ
Cerecor Reports Q1 2020 Results and Update	07/05/20	GL
CERECOR INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	27/04/20	AQ
Cerecor Inc. Announces Executive and Board Changes	27/04/20	CI
Cerecor : Announces Changes to Board of Directors	27/04/20	AQ
Cerecor Announces Changes to Board of Directors	24/04/20	GL
BioNJ :'s 27th Annual Dinner Meeting & Innovation Celebration Honors New Jersey's Innovators and the Patients Who Inspire Them	11/02/20	PR
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	03/02/20	AQ
Aevi Genomic Medicine, Inc. Announces Resignation of Directors	03/02/20	CI
CERECOR INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	03/02/20	AQ

1234NextSee all

Companies (58)

HEINEKEN N.V. 55 050 M $

Heineken N.V. is a food group that specializes in beer brewing under the brands Heineken and Amstel. In 2023, the group brewed 242.6 million hectoliters of beers. The group owns 168 breweries, malteries and cider plants in over 70 countries. Heineken N.V ...

HEINEKEN N.V. 55 050 M $

PEPSICO, INC. 242 B $

PepsiCo, Inc. is one of the worldwide leaders in producing non-alcoholic beverages and snacks. Net sales break down by area of activity as follows: - North America (60.8%): sale of beverages (49.7% of net sales; sodas, concentrated juices, water, tea and ...

PEPSICO, INC. 242 B $

MOLSON COORS BEVERAGE COMPANY 12 267 M $

Molson Coors Beverage Company specializes in the production and marketing of beers. The products are sold under the brands Coors Light, Miller Lite, Molson Canadian, Carling, Staropramen, Coors Banquet, Blue Moon Belgian White, Blue Moon LightSky, Vizzy, ...

MOLSON COORS BEVERAGE COMPANY 12 267 M $

THE CLOROX COMPANY 17 167 M $

The Clorox Company is a world leader in the production and sale of consumer products. Net sales by family of products break down as follows: - home maintenance and laundry products (40.6%): dishwashing liquids, detergents, stain removers, bleaches, toile ...

THE CLOROX COMPANY 17 167 M $

1234Next

Insiders

Sol Barer

Founder of Celgene Corp., Centrexion Therapeutics Corp., Celgene SAS and Barer & Son Capital LLC, Sol J. Barer is an entrepreneur and businessperson who has been the head of 14 different companies and holds the position of Chairman of Teva Pharmaceutical Industries Ltd., Chairman for NexImmune, Inc., Chairman for Centrexion Therapeutics Corp. and Chairman for Cerecor, Inc., Chairman for Medgenics Medical (Israel) Ltd. (a subsidiary of Cerecor, Inc.). He is also Managing Director at SJBarer Consulting LLC and Founding Chairman-Center for Innovation at Hackensack Meridian School of Medicine and on the board of 7 other companies. Sol J. Barer previously held the position of Chairman for InspireMD, Inc., Director at Cerecor, Inc. and Non-Executive Chairman of Aevi Genomic Medicine, Inc. (a subsidiary of Cerecor, Inc.), Director at Rafael Pharmaceuticals, Inc., Executive Chairman at Celgene Corp., Chairman for Edge Therapeutics, Inc., Non-Executive Chairman at RestorGenex Corp., Commissioner for New Jersey Commission on Science & Technology and Chairman for the University of Medicine & Dentistry of New Jersey. Dr. Barer received a doctorate from Rutgers State University of New Jersey and an undergraduate degree from Brooklyn College.

Joshua Barer

Joshua Barer is currently the Chief Executive Officer at Hibiscus Capital Management, Director at AsclepiX.
Therapeutics LLC, and Managing Director at Hibiscus BioVentures LLC.
He is also a Board Member at Trickle Up Program, Inc. and Family Promise, Inc. In the past, he worked as a Venture Capital Associate at Maxim Group LLC and as an Associate at Trout Capital LLC.
He completed his undergraduate degree from Rutgers State University of New Jersey in 2011.

Joe Barer

Stanley H. Barer

Stanley H.
Barer was the founder of Saltchuk Resources, Inc. (founded in 1982) where he held the title of Chairman-Emeritus.
Currently, he is a Trustee at the H.
John Heinz III Center for Science.
Previously, he held the position of Director at The Commerce Bank of Washington, NA and was a Trustee at The Washington Center for Internships & Academic Seminars.
Mr. Barer received his undergraduate degree from the University of Washington and the University of Pennsylvania.

Meri Barer is associated with Overlook Hospital Foundation as a Trustee since 2016.

Alan L. Barer

No results for this search